StreetInsider.com News Articles

ImmunityBio to present cancer drug data at ASCO 2026 meeting

Mon, 01 Jun 2026 13:53:17 -0400

ImmunityBio Inc. (NASDAQ: IBRX) announced it will present data from clinical trials of its cancer immunotherapy drug ANKTIVA at the American Society of Clinical Oncology Annual Meeting scheduled for May 29-June 2, 2026, in Chicago.

The company will present two posters and one online publication covering studies in non-small cell lung cancer and non-muscle invasive bladder cancer. The presentations include data from two randomized Phase 3 trials in advanced non-small cell lung cancer and a matched adjusted indirect comparison study in bladder cancer patients who did not respond to BCG treatment.

ANKTIVA, also known as nogapendekin alfa inbakicept-pmln, is an IL-15 receptor

ImmunityBio to present cancer drug data at ASCO 2026 meeting

Mon, 01 Jun 2026 13:53:17 -0400

ANKTIVA, also known as nogapendekin alfa inbakicept-pmln, is an IL-15 receptor

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago.

The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA® (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Mon, 01 Jun 2026 13:51:00 -0400

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

ImmunityBio presents UK patient survey on bladder cancer treatment preferences

Fri, 22 May 2026 07:30:43 -0400

ImmunityBio Inc. (NASDAQ: IBRX) announced survey data from UK adults with non-muscle-invasive bladder cancer showing varied treatment preferences following BCG therapy failure. The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research conference in Philadelphia.

The study, conducted with Fight Bladder Cancer, surveyed 86 UK adults currently receiving or previously treated with Bacillus Calmette-Guérin therapy for high-risk non-muscle-invasive bladder cancer. Researchers used online questionnaires, interviews and focus groups to examine patient preferences between radical cystectomy and bladder-sparing treatments.

Results showed patients actively receiving BCG were more likely to favor bladder preservation strategies, while those who previously underwent radical cystectomy

ImmunityBio shows cost savings for ANKTIVA plus BCG versus TAR-200

Fri, 22 May 2026 07:30:34 -0400

ImmunityBio Inc. (NASDAQ: IBRX) presented a health economic analysis at ISPOR 2026 demonstrating that ANKTIVA plus BCG treatment showed lower costs per sustained complete response compared to TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.

The analysis, presented May 17-20 at the Pennsylvania Convention Center in Philadelphia, used a cost-consequence model comparing ANKTIVA plus BCG with TAR-200 in a U.S. Medicare population over three years. The study incorporated data from the QUILT-3.032 study for ANKTIVA plus BCG and the SunRISe-1 trial for TAR-200.

Key findings included cost savings per cystectomy avoided of $109,622 at year one, $151,438 at year

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS